WFRF:(Eliasson M)
Search: WFRF:(Eliasson M) > (2010-2014) > The shape of the me...
- 16 of 70
- Previous record
- Next record
- To hitlist
- Lind, MNU-sjukvården,NU Hospital Group (author)
The shape of the metabolic memory of HbA(1c): re-analysing the DCCT with respect to time-dependent effects.
- Article/chapterEnglish2010
Publisher, publication year, extent ...
- 2010-03-18
- Springer Science and Business Media LLC,2010
Numbers
- LIBRIS-ID:oai:gup.ub.gu.se/119187
- https://gup.ub.gu.se/publication/119187URI
- https://doi.org/10.1007/s00125-010-1706-zDOI
- https://research.chalmers.se/publication/119187URI
Supplementary language notes
- Language:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- AIMS/HYPOTHESIS: We determined the shape of the metabolic memory of HbA(1c) and its contribution to retinopathy, as well as the importance of reducing HbA(1c) to prevent progression of retinopathy. METHODS: The relative risk contribution of HbA(1c) values at different points in time to current progression of retinopathy was determined in the DCCT patients. RESULTS: HbA(1c) 2 to 3 years earlier had the greatest relative risk contribution to current progression of retinopathy. HbA(1c) up to 5 years earlier made a greater contribution than current values, while values from 8 years earlier still had an important impact. When HbA(1c) had been at 8% for a long period and was subsequently lowered to 7%, the salutary effects did not begin to appear until 2 to 3 years after lowering. The hazard function for a constant level of HbA(1c) increased with time. The numbers needed to treat when reducing HbA(1c) from 8.3% to 8% from diagnosis was estimated to be 1,688 for the first 3 years and 13 for the period 9 to 12 years. Survival functions when reducing HbA(1c) from 8% to 7% show that pre-study glycaemic control dominates the effect on progression of retinopathy during the first years of a trial. CONCLUSIONS/INTERPRETATION: The most harmful effect of hyperglycaemia on progression of retinopathy in type 1 diabetes initially increases, but declines after roughly 5 years. The salutary effect of reducing HbA(1c) accelerates with time and becomes greater in clinical practice than has been previously understood. Clinical trials should preferably be designed for long periods or include patients with low previous glycaemic exposure to distinguish trial effects from those of the metabolic memory.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Odén, Anders,1942Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper, matematisk statistik,Department of Mathematical Sciences, Mathematical Statistics,University of Gothenburg,Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)odena (author)
- Fahlén, M (author)
- Eliasson, Björn,1959Sahlgrenska universitetssjukhuset,Sahlgrenska University Hospital(Swepub:gu)xelibj (author)
- NU-sjukvårdenInstitutionen för matematiska vetenskaper, matematisk statistik (creator_code:org_t)
Related titles
- In:Diabetologia: Springer Science and Business Media LLC53:6, s. 1093-10981432-04280012-186X
Internet link
- 16 of 70
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Lind, M
- Odén, Anders, 19 ...
- Fahlén, M
- Eliasson, Björn, ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Endocrinology an ...
- Articles in the publication
- Diabetologia
- By the university
- University of Gothenburg
- Chalmers University of Technology
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
